Machavert Pharmaceuticals Unveils a New Bioactive Lipid Drug Candidate for Cancer Treatment

NOV 26, 2018 Science

Press release (PR Newswire)

Aurora, CO November 26, 2018 /PRNewswire/ – Machavert Pharmaceuticals, a drug development company focused on bioactive phospholipid therapeutics for the treatment of cancer, recently reported impressive preclinical results. The company announced the progress of its MP1000 candidate at the European Organization for Research and Treatment of Cancer (EORTC)-National Cancer Institute (NCI)-American Association of Cancer Research (AACR) Annual Symposium 2018 in Dublin, Ireland.

„The data presented at EORTC demonstrated MP1000 anti-tumor activity in a diverse range of models including KRAS mutant solid tumors, as well as in liquid tumor models. KRAS mutant tumors may represent up to 30% of all cancers and offering a unique therapeutic approach will be advantageous to patients that have few precision medicine treatment options for these types of cancers,“ said Dr. Neal Goodwin, Chief Scientific Officer at Machavert. „We also observed inhibition of tumor growth in aggressive indolent non-Hodgkin’s lymphoma (NHL), acute myeloid leukemia (AML), and multiple myeloma models. Additionally, MP1000 formulated as nanoparticles was successfully shown to deliver a payload test compound to NHL cells and offer increased anti-tumor proliferative activity.”

The efficacy of MP1000 monotherapy is currently being investigated in human immune system tumor models. The drug candidate is currently entering preclinical IND-enabling studies, a prerequisite for seeking an FDA IND approval for human clinical trial entry.

About Machavert Pharmaceuticals

Machavert Pharmaceuticals is a preclinical stage drug development company focused on advanced therapies based on its proprietary bioactive phospholipid platform for the treatment of multiple cancers in hematology and solid tumor oncology. The phospholipid platform is also being combined with other therapeutics such as small molecules for precision medicine and immuno-oncology. Machavert’s core focus is on a difficult-to-treat driver mutations and other orphan indications in oncology.